4//SEC Filing
Perkins Adelene Q 4
Accession 0000899243-18-025797
CIK 0001113148other
Filed
Oct 1, 8:00 PM ET
Accepted
Oct 2, 4:30 PM ET
Size
6.5 KB
Accession
0000899243-18-025797
Insider Transaction Report
Form 4
Perkins Adelene Q
Pres & Chief Business Officer
Transactions
- Sale
Common Stock
2018-10-01$2.82/sh−5,000$14,100→ 609,561 total
Holdings
- 16,446.795(indirect: By 401(k))
Common Stock
Footnotes (3)
- [F1]The disposition reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2017.
- [F2]The price reported in this line of Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.80 to $2.88, inclusive. The reporting person undertakes to provide to Infinity Pharmaceuticals, Inc., any security holder of Infinity Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2.
- [F3]Includes 7,309 shares of common stock acquired by Ms. Perkins on June 16, 2018 through participation in the issuer's Employee Stock Purchase Plan.
Documents
Issuer
INFINITY PHARMACEUTICALS, INC.
CIK 0001113148
Entity typeother
Related Parties
1- filerCIK 0001375124
Filing Metadata
- Form type
- 4
- Filed
- Oct 1, 8:00 PM ET
- Accepted
- Oct 2, 4:30 PM ET
- Size
- 6.5 KB